Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia

NCT03187691 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Protocol redundancy

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: Oral Encochleated Amphotericin B (CAMB)

Sponsor

Matinas BioPharma Nanotechnologies, Inc.

Collaborators

[object Object]
[object Object]